ICU Medical, Inc. (ICUI)
NASDAQ: ICUI · IEX Real-Time Price · USD
95.53
+1.00 (1.06%)
Apr 26, 2024, 1:07 PM EDT - Market open
ICU Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ICU Medical stock have an average target of 123, with a low estimate of 110 and a high estimate of 136. The average target predicts an increase of 28.76% from the current stock price of 95.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 28, 2024.
Analyst Ratings
The average analyst rating for ICU Medical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $134 → $136 | Buy | Maintains | $134 → $136 | +42.36% | Feb 28, 2024 |
| Keybanc | Keybanc | Buy Initiates $134 | Buy | Initiates | $134 | +40.27% | Feb 6, 2024 |
| CL King | CL King | Strong Buy Initiates $110 | Strong Buy | Initiates | $110 | +15.15% | Dec 14, 2023 |
| Keybanc | Keybanc | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 9, 2023 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 8, 2022 |
Financial Forecast
Revenue This Year
2.32B
from 2.26B
Increased by 2.87%
Revenue Next Year
2.41B
from 2.32B
Increased by 3.79%
EPS This Year
4.82
from -1.23
EPS Next Year
6.91
from 4.82
Increased by 43.32%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 2.4B | 2.5B | 2.6B | 2.7B |
| Avg | 2.3B | 2.4B | 2.5B | 2.6B |
| Low | 2.2B | 2.3B | 2.3B | 2.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 6.5% | 7.8% | 7.9% | 9.4% |
| Avg | 2.9% | 3.8% | 2.9% | 6.3% |
| Low | -1.5% | -2.2% | -3.0% | 2.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 5.02 | 7.68 | 9.35 | 13.64 |
| Avg | 4.82 | 6.91 | 8.46 | 13.25 |
| Low | 4.55 | 6.37 | 7.53 | 12.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 59.2% | 35.2% | 61.3% |
| Avg | - | 43.3% | 22.3% | 56.7% |
| Low | - | 32.1% | 8.9% | 50.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.